Anti-phospholipid antibodies (aPL) and lupus anticoagulant (LAC) represent diagnostic criteria for systemic lupus erythematosus (SLE) and underlie anti-phospholipid syndrome (APS) in patients with and without SLE. 526 healthy controls and 1633 SLE and 1835 primary APS (PAPS) patients were evaluated. LAC was assessed by hexagonal phase phospholipid neutralization assay (HPPNA), diluted Russell viper venom test (dRVVT), and platelet neutralization procedure (PNP). β2-glycoprotein-I and cardiolipin IgG, IgM, and IgA antibodies (aCL-IgG, aCL-IgM, aCL-IgA) were measured. 222/1633 SLE patients had APS based on the nine-test panel, which afforded the highest sensitivity (74%) and negative predictive value (90%) but lowest specificity (52%). HPPNA was the most sensitive individual test at 52%. The nine-test panel yielded the greatest sensitivity for aPL detection (70%) relative to HPPNA, the most sensitive individual test (36%) in PAPS. Superior sensitivity of a nine-test aPL panel has major implications for preventing potentially fatal thrombotic events in SLE and PAPS.

中文翻译：

---

九个检测组对检测患有或未患有 SLE 的患者的抗磷脂抗体综合征具有卓越的敏感性。

抗磷脂抗体 (aPL) 和狼疮抗凝剂 (LAC) 是系统性红斑狼疮 (SLE) 的诊断标准，是 SLE 患者和非 SLE 患者抗磷脂综合征 (APS) 的基础。评估了 526 名健康对照和 1633 名 SLE 和 1835 名原发性 APS (PAPS) 患者。LAC 通过六角相磷脂中和试验 (HPPNA)、稀释的罗素蝰蛇毒试验 (dRVVT) 和血小板中和程序 (PNP) 进行评估。测量了 β2-糖蛋白-I 和心磷脂 IgG、IgM 和 IgA 抗体（aCL-IgG、aCL-IgM、aCL-IgA）。222/1633 名 SLE 患者基于 9 个测试组具有 APS，其敏感性最高 (74%) 和阴性预测值 (90%)，但特异性最低 (52%)。HPPNA 是最敏感的个体测试，为 52%。与 HPPNA（PAPS 中最敏感的单个测试（36%））相比，九个测试组对 aPL 检测的灵敏度最高（70%）。九个测试 aPL 面板的卓越灵敏度对于预防 SLE 和 PAPS 中潜在的致命血栓事件具有重要意义。